SAB Biotherapeutics reports Q2 EPS (14c) vs (11c) last year

“We are pleased to share the significant progress achieved during the second quarter of 2023. Our commitment to advancing transformative immunotherapies remains unwavering, with a renewed strategic focus on Type 1 Diabetes through our SAB-142 program, a first-in-class fully human immunotherapeutic being developed for delaying onset and progression of Type 1 Diabetes. SAB-142 is a purified, fully human polyclonal anti-thymocyte globulin, which we believe is a promising solution for the limitations and side effects often associated with existing rabbit-derived ATG treatments. The promising safety and pharmacologic data from the GLP toxicology study for SAB-142, presented at the Federation of Clinical Immunology Societies conference, underscored its potential to reshape diabetes treatment,” said Eddie J. Sullivan, Ph.D., Co-Founder, President, and Chief Executive Officer of SAB Biotherapeutics. “Our recent R&D Day, featuring SAB-142 as a centerpiece, further solidified our dedication to addressing autoimmune disorders with significant unmet needs. Furthermore, our influenza therapy, SAB-176, was highlighted at prominent industry events like the BIO 2023 International Convention and the International Society for Influenza and Other Respiratory Virus Diseases conference. Additionally, we achieved a regulatory milestone with FDA approval for five sections of our New Animal Drug Application, a pivotal step for our DiversitAb production system and hIgG antibody investigational drugs. As we continue to navigate dynamic medical landscapes, we remain steadfast in our mission to deliver impactful immunotherapies for the betterment of patients worldwide.”